Head-to-head · WeighScore
EllieMD vs MadeMed
By GLP-1 ScorecardUpdated
Score comparison
MadeMed has the higher recorded score — 80.4/100 to 55/100.
MadeMed grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MadeMed advertises all-dose pricing across 30-, 90- and 360-day purchases, with a consultation-fee conflict to resolve before prepaying.
Before you choose
EllieMD does not publish a semaglutide price, so its EllieMD review sets out what it does disclose, while the MadeMed review explains the conditions attached to MadeMed's figure. The semaglutide cost page compares published rates across the field. Ask EllieMD for a written total before treating either one as the cheaper choice.
If neither one fits, EllieMD vs No BS RX and EmbraceRX vs MadeMed compare each of them with another graded program, and the list of alternatives to EllieMD ranks the programs closest to EllieMD on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the MyDrHank review covers one graded close to these two, at 68.2/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | EllieMD | MadeMed |
|---|---|---|
| WeighScore | 55/100 | 80.4/100 |
| Grade | C | B− |
| Site position | #477 | #35 |
| Semaglutide | GLP-1 program quote required; confirm exact ingredient | $179 every 30 days; $483/90 days or $1,718/360 days ($143.17 equivalent per 30 days); consultation fees and usable supply require confirmation |
| Tirzepatide | GLP-1/GIP program quote required; confirm exact ingredient | Injection or sublingual: $249 every 30 days; $672/90 days or $2,390/360 days ($199.17 equivalent per 30 days); final fees and supply unverified |
| Coverage | Conflicting all-50 and most-states claims; shipping subject to product-specific exemptions; confirm eligibility | Confirm selected treatment/state: sublingual tirzepatide FAQ lists 40 states; current injection-state map unverified |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #477 · C
Strengths
- Offers compounded injection and oral-drop formats
- Describes provider messaging, 12-week reassessment and community events
- Policy refunds product payment after medical ineligibility; separate assessment fee considered case by case
What to consider
- Initial three-month minimum remains payable when using installments
- Cancel through the portal at least 48 hours before renewal; active-term installments remain due
- Successfully canceled new orders can incur a $99 administrative deduction before transmission; no refund after pharmacy processing
- Exact active ingredient and all-in price remain unsettled; FDA-approval wording conflicts
- All-50-state claims are qualified by most-states wording and product-specific shipping exemptions
Site position #35 · B−
Strengths
- Public selectors show full charges for 30-, 90- and 360-day plans across the listed GLP-1 products
- Advertises the same pricing across doses, ongoing clinical messaging and included injection supplies
- Current terms name MDI Medical Group PC and four partner pharmacy brands
- A 30-day purchase is advertised alongside the larger prepaid options
What to consider
- Lowest advertised equivalents require $1,718/$2,390 360-day billing plans; terms reject prorated refunds
- Product pages list $20/$30 consultation fees while How It Works says consultation is included and ineligible payments are refunded in full
- The forty-state claim is specific to sublingual tirzepatide; an injection-state map was not established
- Assigned clinician/pharmacy branch, patient lab costs, final first debit and usable prescription supply remain unresolved
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.